<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892917</url>
  </required_header>
  <id_info>
    <org_study_id>G1217</org_study_id>
    <nct_id>NCT01892917</nct_id>
  </id_info>
  <brief_title>BIOFLOW-III Hungary Satellite Registry</brief_title>
  <official_title>BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Hungary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik Hungária Kft.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik Hungária Kft.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring
      coronary revascularization with Drug Eluting Stents (DES)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal
      Coronary Angioplasty (PTCA) provides high initial procedural success. However, the medium to
      long-term complications range from rather immediate elastic recoil or vessel contraction to
      longer processes like smooth muscle cell proliferation and excessive production of extra
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from
      30%-50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents
      (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical
      restenosis rates in de novo lesions compared to PTCA alone and decreased the need for CABG.
      BMS substantially reduced the incidence of abrupt artery closure, but restenosis still
      occurred in about 20%-40% of cases, necessitating repeat procedures. The invention of Drug
      Eluting Stents (DES) significantly improved on the principle of BMS by adding an
      antiproliferative drug (directly immobilised on the stent surface or released from a polymer
      matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the
      incidence of restenosis and resulted in a better safety profile as compared to BMS with
      systemic drug administration. These advantages and a lower cost compared to surgical
      interventions has made DES an attractive option to treat coronary artery disease. This
      observational registry is designed to investigate and collect clinical evidence for the
      clinical performance and safety of the Orsiro Drug Eluting Stent System in an all-comers
      patient population in daily clinical practice
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsors Decision. The collected data are available in a significant proportion and
    sufficiently enough for an adequate analysis.
  </why_stopped>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>6 and 18 months</time_frame>
    <description>Any target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Any repeat revascularization of the target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Any repeat revascularization of the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>Definite, possible and probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Device Success</measure>
    <time_frame>At time of intervention</time_frame>
    <description>Clinical Device Success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>During the hospital stay to a maximum of the first seven days post index procedure</time_frame>
    <description>Clinical Procedural Success</description>
  </secondary_outcome>
  <enrollment type="Actual">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All-comers patient population with all subjects requiring coronary revascularization with a
        Drug Eluting Stent (DES)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic coronary artery disease

          -  Subject has signed informed consent for data release

          -  Subject is geographically stable and willing to participate at all follow-up
             assessments

          -  Subject is ≥ 18 years

        Exclusion Criteria:

          -  Subject did not sign informed consent for data release

          -  Pregnancy - Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any
             other anticoagulation / antiplatelet therapy required for PCI, stainless steel,
             Sirolimus or contrast media

          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be
             maintained

          -  Currently participating in another study and primary endpoint is not reached yet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béla Merkely, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Állami Szívkórház (State Hospital for cardiology of Balatonfüred)</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8231</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet (Gottsegen György Hungarian Institute of Cardiology)</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Kórház (Bajcsy-Zsilinszky Hospital)</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE ÁOK Kardiológiai Központ (Semmelweis University, Heart Center)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DEOEC, Kardiológiai Intézet ( Institute of Cardiology, University of Debrecen)</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Oktató Kórház, Kardiológia (Kaposi Mór Teaching Hospital, Cardiology)</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jósa András Kórház, Kardiológia (Jósa András Hospital, Department of Cardiology)</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE ÁOK Szívcentrum (University of Pécs, Faculty of Medicine, Heart Institute)</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szentgyörgyi Albert Tudomány Egyetem, ÁOK, Kardiológia (University of Szeged, Albert Szent-Györgyi Clinical Center, Faculty Of Medicine, Second Department of Medicine and Cardiology Centre)</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház, Kardiológia-Hemodinamika (Jász-Nagykun-Szolnok County, Hetényi Géza Hospital, Cardiology, Haemodynamics)</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas Megyei Markusovszky Kórház Zrt (Vas County, Markusovszky Hospital)</name>
      <address>
        <city>Szombathely</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejér Megyei Szent György Kórház (Fejér County Szent György Hospital)</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8001</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Kórház, Kardiológia (Zala County Hospital, Cardiology)</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2013</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stent (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of Coronary Artery Disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Subgroups</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Small Vessels</keyword>
  <keyword>Chronic Total Occlusion (CTO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

